All In Biotech

Drug Trial Radar · NCT07090759

To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Trial of GST-HG141(Neracorvir)for Combination Therapy (add-on) in Patients With Inadequate Response to Antiviral Drugs in Chronic Hepatitis B (CHB)

Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 526 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

526

Planned (sponsor's estimate)

Start

Jul 24, 2025

Primary completion

Dec 1, 2026

Study completion Mar 1, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GST-HG141 in patients with chronic hepatitis B who have an inadequate response to antiviral drug treatment.

Conditions

  • Chronic Hepatitis b

Interventions

  • GST-HG141Drug

    GST-HG141 50 mg BID

  • GST-HG141 PlaceboDrug

    GST-HG141 Placebo BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with serum Hepatitis B Virus (HBV) DNATime frame: Up to 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shulan(Hangzhou) Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.